Review
doi: 10.1016/j.jns.2004.04.015.
Mechanisms of mitoxantrone in multiple sclerosis--what is known?
Affiliations
- PMID: 15261556
- DOI: 10.1016/j.jns.2004.04.015
Item in Clipboard
Review
Mechanisms of mitoxantrone in multiple sclerosis--what is known?
J Neurol Sci.
.
Abstract
The recent publication of the MIMS-study (Mitoxantrone In Multiple Sclerosis) and the approval of several health authorities support the use of mitoxantrone in patients with active relapsing-remitting or secondary progressive multiple sclerosis. This review provides information on data thus far present on the putative mechanisms of action of mitoxantrone in the immunopathogenesis of this disabling disease.
Copyright 2004 Elsevier B.V.
Similar articles
-
Therapeutic role of mitoxantrone in multiple sclerosis.Pharmacol Ther. 2006 Jan;109(1-2):198-209. doi: 10.1016/j.pharmthera.2005.07.002. Epub 2005 Aug 10. Pharmacol Ther. 2006. PMID: 16095713 Review.
-
Mitoxantrone and cytotoxic drugs' mechanisms of action.Neurology. 2010 Jan 5;74 Suppl 1:S41-6. doi: 10.1212/WNL.0b013e3181c97f5a. Neurology. 2010. PMID: 20038762
-
Rationale for the use of mitoxantrone in multiple sclerosis.J Neurol Sci. 2004 Aug 15;223(1):35-9. doi: 10.1016/j.jns.2004.04.017. J Neurol Sci. 2004. PMID: 15261558 Review.
-
Management of worsening multiple sclerosis with mitoxantrone: a review.Clin Ther. 2006 Apr;28(4):461-74. doi: 10.1016/j.clinthera.2006.04.013. Clin Ther. 2006. PMID: 16750460 Review.
-
Mitoxantrone (Novantrone) in multiple sclerosis: new insights.Expert Rev Neurother. 2004 Jan;4(1):17-26. doi: 10.1586/14737175.4.1.17. Expert Rev Neurother. 2004. PMID: 15853611 Review.
Cited by
-
The Diversity of Astrocyte Activation during Multiple Sclerosis: Potential Cellular Targets for Novel Disease Modifying Therapeutics.Healthcare (Basel). 2023 May 29;11(11):1585. doi: 10.3390/healthcare11111585. Healthcare (Basel). 2023. PMID: 37297725 Free PMC article. Review.
-
Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options.Drugs. 2019 Feb;79(2):125-142. doi: 10.1007/s40265-018-1039-7. Drugs. 2019. PMID: 30623348 Review.
-
Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis.Int J Mol Sci. 2020 Jun 17;21(12):4312. doi: 10.3390/ijms21124312. Int J Mol Sci. 2020. PMID: 32560364 Free PMC article. Review.
-
Current and future treatment approaches for neuromyelitis optica.Ther Adv Neurol Disord. 2011 Mar;4(2):111-21. doi: 10.1177/1756285611398939. Ther Adv Neurol Disord. 2011. PMID: 21694808 Free PMC article.
-
Immunological Aspects of Approved MS Therapeutics.Front Immunol. 2019 Jul 11;10:1564. doi: 10.3389/fimmu.2019.01564. eCollection 2019. Front Immunol. 2019. PMID: 31354720 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
